Humanetics welcomes Tom Jasper to its Board of Directors

– USA, MN –  Humanetics Corporation, a clinical-stage specialty pharmaceutical company, announced the addition of Tom Jasper to its board of directors.

“Tom has been an investor and advisor to the Company for several years. He has exceptional expertise in both strategy and corporate development and brings deep experience in financial management, government relations, and corporate governance. Tom’s energy and acumen have already contributed to our positive momentum at Humanetics,” said CEO, Ron Zenk.

About Tom Jasper

Tom Jasper is currently the Managing Partner of Protagonist Path LLC, a privately held investment and advisory firm. The firm makes investments across multiple industries and provides advisory services to its clients. Previously, Mr. Jasper was the Vice Chairman and COO of TCF Financial Corporation. He served as a board member at TCF from 2012 through 2019 and as its CFO from 2006 to 2012. As COO, Mr. Jasper was responsible for strategy and corporate development, as well as other corporate functions including investor relations, government relations, legal, human capital management, finance, and corporate operations. He was instrumental to TCF’s successful growth and diversification during his 18-year career at the company. Mr. Jasper has extensive leadership experience in a variety of debt and equity offerings in various economic and interest rate environments, as well as ample experience in the federal government and regulatory relations.

“I’m excited to start my service on the board of directors and to begin working alongside my fellow directors and the management team at Humanetics to deliver shareholder value,” commented Tom Jasper. “From my first interaction with the company, I understood the very real potential to solve urgent and unmet medical needs for our armed forces, first responders, civilian populations, cancer radiation therapy patients, and those recovering from serious cases of COVID-19. The management team has done great work developing BIO 300 for these important missions.”

About Humanetics Corporation

Humanetics is a clinical-stage specialty pharmaceutical company engaged in the accelerated discovery, development, and commercialization of proprietary drugs in markets with urgent and unmet needs, with a focus on medical countermeasures to prevent harm caused by exposure to radiation, for protective use in cancer radiation therapy, and to guard against the long-term damaging effects of COVID-19.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.